Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Breast 2Tumor-Agnostic 1Genitourinary 1

Conditions

Breast Neoplasms 2Ovarian Neoplasms 1Neuralgia 1

Interventions

Trastuzumab 732Paclitaxel 695Cyclophosphamide 647Docetaxel 560Capecitabine 486Letrozole 437Fulvestrant 400Carboplatin 398Doxorubicin 341Tamoxifen 308Anastrozole 279pembrolizumab 274exemestane 258Epirubicin 251pertuzumab 240Radiotherapy 239palbociclib 224Bevacizumab 222Gemcitabine 215Vinorelbine 197Lapatinib 181130-nm albumin-bound paclitaxel 172Magnetic Resonance Spectroscopy 164Albumin-Bound Paclitaxel 157eribulin 154Surveys and Questionnaires 152Exercise 151Drug Therapy 141Taxes 134Fluorouracil 133

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Telmisartan × Breast × Clear all
NCT07370506 2026-01-29

Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients

Tanta University

Phase 1/2 Not yet recruiting
36 enrolled
Breast

Breast Neoplasms

NCT05322889 2024-08-28

PrevTel

Fraunhofer Institute for Translational Medicine and Pharmacology ITMP

Phase 2 Completed
35 enrolled
BreastGynecologic

Breast Neoplasms, Neuralgia, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡